AstraZeneca plc’s Sell Rating Reaffirmed at Societe Generale (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “sell” rating reiterated by analysts at Societe Generale in a research report issued to clients and investors on Friday. They currently have a GBX 3,740 ($63.51) target price on the stock. Societe Generale’s price objective suggests a potential downside of 13.91% from the stock’s previous close.
Shares of AstraZeneca plc (LON:AZN) opened at 4279.00 on Friday. AstraZeneca plc has a one year low of GBX 3086.50 and a one year high of GBX 5750.00. The stock has a 50-day moving average of GBX 4381. and a 200-day moving average of GBX 4171.41. The company’s market cap is £53.958 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Deutsche Bank raised their price target on shares of AstraZeneca plc from GBX 3,950 ($67.07) to GBX 4,000 ($67.92) in a research note on Friday. They now have a “hold” rating on the stock. Separately, analysts at Berenberg Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday. They now have a GBX 3,775 ($64.10) price target on the stock. Finally, analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday. They now have a GBX 4,790 ($81.34) price target on the stock. Seven investment analysts have rated the stock with a sell rating, seventeen have given a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of GBX 4,062.63 ($68.99).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.